Ligands to the integrin receptor _v₃

In this: publication
By this: publisher
In this Subject: <a title="Pharmacology" href="/content/subcat;jsessionid=25gqh0plpuvvu.victoria?j_subject=212&j_availability=">Pharmacology
By this author: <a href="/search;jsessionid=25gqh0plpuvvu.victoria?option2=author&value2=Duggan+ME">Duggan M.E. ;&nbsp; <a href="/search;jsessionid=25gqh0plpuvvu.victoria?option2=author&value2=Hutchinson+JH">Hutchinson J.H.

Authors: Duggan M.E.; Hutchinson J.H.

Source: Expert Opinion on Therapeutic Patents, Volume 10, Number 9, September 2000 , pp. 1367-1383(17)

Buy & download fulltext article:

Price: $113.00 plus tax (Refund Policy)

Abstract:

The vitronectin receptor _v bgr ₃ is a member of the integrin superfamily of membrane bound glycoprotein receptors that is responsible for cell-cell and cell-matrix interactions and shares the same bgr subunit as the fibrinogen receptor _IIb bgr ₃ (also known as GPIIb/IIIa). Both these integrins recognise extracellular proteins that express the peptide sequence arginine-glycine-aspartic acid (RGD). Non-peptide RGD mimetics that bind with high affinity and selectivity to _IIb bgr ₃ were previously prepared as anti-thrombotic agents. More recently, medicinal chemistry groups have modified these non-peptide fibrinogen receptor antagonist lead structures to impart potency and integrin selectivity for _v bgr ₃. Numerous patent applications and issued patents have appeared throughout the last decade claiming structurally novel _v bgr ₃ antagonists as agents for the prevention and/or treatment of osteoporosis, cancer, diabetic retinopathy and rheumatoid arthritis. This review encompasses those issued patents and published patent applications that disclose ligands to _v bgr ₃.